A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard of care (SOC) of LONSURF (trifluridine and tipiracil) plus bevacizumab in adult participants with c-Met over-expressed refractory metastatic colorectal cancer (mCRC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants will then be randomized into 2 groups called treatment arms. One group will receive t

Trial Details

NCT ID
NCT07525206
Phase
PHASE3
Sponsor
AbbVie
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Telisotuzumab adizutecan
  • Bevacizumab
  • Trifluridine/Tipiracil
Locations (sample)
  • East Brunswick, New Jersey, United States|40.42788,-74.41598
  • Lake Success, New York, United States|40.77066,-73.71763
  • Portland, Oregon, United States|45.52345,-122.67621
  • Seattle, Washington, United States|47.60621,-122.33207
  • Bonheiden, Antwerpen, Belgium|51.02261,4.54714

Key Eligibility Criteria

  • Must voluntarily sign and date an informed consent, approved by an Ethics Committee (IEC)/ Institutional Review Board (IRB), prior to the initiatio…
  • Life expectancy \>= 12 weeks per investigator assessment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →